New biomarker identified to prevent heart attacks and stroke

22 August 2014

Researchers in Finland have determined that low expression of a fatty acid-binding protein - FABP4 - reduces the risk of heart attack and stroke. These findings, published in the journal Circulation: Cardiovascular Genetics, could offer a potential for a new preventive drug for atherosclerosis.

Led by Professor Perttu Lindsberg, the findings are part of a long-term research project of the Department of Neurology at the Hospital District of Helsinki and Uusimaa (HUS). It suggests that people who inherit a genetic variant, which reduces levels of FABP4, from both parents have eight-fold lower odds for myocardial infarction than the rest of the population.

The researchers also discovered that patients with carotid stenosis who carried the protective gene variant suffered from strokes three times less frequently than people who had the condition but were without the gene.

This study is the first to determine a link between the FABP4 variant and a lower level of cholesterol in the blood, but the researchers found that the most noticeable decrease was found in obese patients.

Posted by Philip Briggs​


Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)